Navigation Links
Enox Biopharma Will Present Its Unique Self-Sterilizing Urinary Catheter at the 49th Annual ICAAC Meeting.
Date:9/11/2009

VANCOUVER, British Columbia, Sept. 11 /PRNewswire/ -- Enox Biopharma, Inc., a medical-device company, dedicated to the commercializing of a unique drug eluting technology for preventing microbial infections associated with certain medical devices, announced today that it will present full details of the successful development of the self-sterilizing urinary catheters at the 2009 Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) which convenes in San Francisco, September 12-15. The world's largest convention of its kind, the ICAAC brings together more than 10,000 physicians, researchers and other healthcare professionals to foster worldwide solutions to the problem of infectious diseases.

At ICAAC, Dr. Gilly Regev-Shoshani, a UBC research associate working on this project, and Dr. Chris Miller, a UBC clinical assistant professor and a director of Enox, will present data outlining the Enox urinary catheter's ability to slowly release nitric oxide into a solution over the course of two weeks. The result: a self-sterilizing process, which prevents biofilm formation on the catheter, inhibits bacterial growth in the area immediately surrounding the catheter without lingering within the body. Nitric oxide exhibits strong activity against a wide range of pathogens and is part of the body's innate response to infections. Enox's innovative approach addressing hospital acquired infections offers significant advantages over other antiseptic coating or drug eluting technologies. Nitric oxide releasing catheters are less toxic to the human body; they remain effective over a longer period of time; and they present limited risk, if any, to developing antibiotic resistance to various bacterial strains.

Enox's First Product, a Self-Sterilizing Urinary Catheter

A team lead by Professor Yossef Av-Gay , of the Faculty of Medicine, University of British Columbia and the Founder and CEO of Enox, has developed a patented, self-sterilizing catheter that, in a controlled process, slowly releases small amounts of nitric oxide gas molecules. Nitric oxide prevents biofilm formation and bacterial growth, addressing a growing concern: catheter-associated urinary infection which is the most common hospital acquired infection, affecting over one million people annually in the U.S. alone.

Hospital acquired infections are critically interconnected with the increasing threat of antimicrobial resistance. They are frequently caused by bacteria that have become resistant to multiple antibiotics. More than half of these infections are attributed to the use of in-dwelling medical devices such as urinary catheters. Hospital acquired infections can be formed when bacteria attach themselves to medical devices, including urinary catheters, forming microbial biofilms that are particularly adept at developing drug resistance. With the heightened attention to this problem, medical professionals have been developing various strategies to lower the rates of infections without being compelled to reduce the number of devices used.

Safe Harbor Statement

This press release contains certain forward-looking statements. Forward-looking statements may include our statements regarding our goals, beliefs, strategies, objectives, plans, including product and service developments, future financial conditions, results or projections or current expectations. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential" or "continue," the negative of such terms, or other comparable terminology. These statements are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause actual results to be materially different from those contemplated by the forward-looking statements. Further information on potential factors that could affect our business is described under the heading "Risks Related to Our Business" in Part I, Item 1, "Description of Business" of our Annual Report on Form 10-K for the fiscal year ended December 31, 2008 and in our registration statement on Form S-1 no. 333-154763, which was declared effective on October 31, 2008. Except as otherwise required by law, Enox Biopharma, Inc. undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

    Contact:
    Enox Biopharma, Inc.
    +1 (604) 637-9744
    info@enoxbiopharma.com


'/>"/>
SOURCE Enox Biopharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Helix BioPharma Closes Private Placement
2. PDL BioPharma Provides Third Quarter 2009 Revenue Guidance of Approximately $71 Million
3. Helix BioPharma Announces $13.5 Million Private Placement
4. Helix Biopharma to Present at the Rodman & Renshaw 11th Annual Healthcare Conference
5. DOR BioPharma to Present at the Rodman & Renshaw Annual Global Investor Healthcare Conference
6. Eiger BioPharmaceuticals Appoints Paul Truex to Board of Directors
7. DOR BioPharma Reports 2nd Quarter and 1st Half 2009 Financial Results and Reviews Recent Accomplishments
8. Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2009 Financial Results
9. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2009 Financial Results on Thursday, August 6, 2009 at 8:30am EDT
10. Eiger BioPharmaceuticals Acquires Exclusive License to Novel Hepatitis C Virus (HCV) Technology From Stanford University
11. DOR BioPharma Receives FDA Orphan Drug Designation for orBec(R) for the Treatment of Chronic Gastrointestinal GVHD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... ... May 03, 2016 , ... Leading CEOs ... on May 31st and June 1st at The Four Seasons Hotel Boston. , ... the life sciences, offering exclusive access to key decision makers who influence deal ...
(Date:5/3/2016)... - And Other Rising Companies ... Those Competitor Biologics  - Biosimilar Drug Producers ... ,  Who are the most important and ... their sales potentials? Discover, in our updated survey, organisations, ... and revenue forecasting. Visiongain,s new ...
(Date:5/2/2016)... -- Q BioMed Inc. (QBIO), a biotechnology ... Inc. will be attending the Association for Research in ... 1-5, 2016 in Seattle Washington . ... and research partners. The meeting provides organizations the opportunity ... opportunities for the MAN-01 program for treatment of glaucoma. ...
(Date:4/29/2016)... ... April 30, 2016 , ... The MIT bioLogic design team has ... team explored how bacterial properties can be applied to fabric and formed into living ... move in response to humidity change. The team harvested Natto cells and applied them ...
Breaking Biology Technology:
(Date:4/14/2016)... April 14, 2016 BioCatch ... Detection, today announced the appointment of Eyal Goldwerger ... role. Goldwerger,s leadership appointment comes at a ... of the deployment of its platform at several of ... technology, which discerns unique cognitive and physiological factors, is ...
(Date:3/29/2016)... 2016 LegacyXChange, Inc. (OTC: ... SelectaDNA/CSI Protect are pleased to announce our successful effort ... variety of writing instruments, ensuring athletes signatures against counterfeiting ... from athletes on LegacyXChange will be assured of ongoing ... Bill Bollander , CEO states, "By ...
(Date:3/21/2016)... Unique technology combines v ... security   Xura, Inc. ... digital communications services, today announced it is working alongside ... customers, particularly those in the Financial Services Sector, the ... within a mobile app, alongside, and in combination with, ...
Breaking Biology News(10 mins):